Adding tumor-treating fields to maintenance temozolomide chemotherapy significantly prolonged progression-free survival and overall survival in patients with glioblastoma who had completed standard chemoradiation therapy, according to an interim analysis published in JAMA.1
Tumor-treating fields are a locoregionally delivered antimitotic treatment that disrupts cell division and organelle assembly.
Researchers sought to evaluate the efficacy and safety of tumor-treating fields in combination with temozolomide as maintenance therapy after chemoradiotherapy for patients with glioblastoma, the deadliest type of primary malignancy of the central nervous system in adults.
For the study, researchers enrolled 315 patients with glioblastoma who had completed chemoradiotherapy. Participants were randomly assigned 2:1 to receive maintenance treatment with either tumor-treating fields delivered for more than 18 hours/day via 4 transducer arrays placed on the scalp and connected to a portable medical device plus temozolomide 150 to 200 mg/m2/day for 5 days of each 28-day cycle or temozolomide alone.
Results of an interim analysis showed that at a median follow-up of 38 months, median progression-free survival was 7.1 months (95% CI 5.9-8.2) in the combination arm and 4.0 months (95% CI 3.3-5.2) in the temozolomide alone arm (HR, 0.62; 98.7% CI 0.43-0.89; P=.001).
Researchers found that median overall survival was 20.5 months (95% CI 16.7-19.1) and 15.6 months (95% CI 13.3-19.1), respectively, (HR, 0.64; 99.4% CI 0.42-0.98; P=.004).
1. Stupp R, Taillbert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA. 2015;314(23):2535-2543.